Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ankur Sethi

Interventional Cardiology Oak Park, IL Medical Doctor

NPI 1013172329 CMS profile 227220

7035 North Ave, 1200 US Highway 22 East, Oak Park, IL 60302

Open in the dashboard

General payments

$34,409

431 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ankur Sethi of Oak Park, IL is reported in the CMS Open Payments database as having received $34,409 across 431 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,461 105
2024 General $5,097 68
2023 General $7,474 87
2022 General $2,220 41
2021 General $2,341 29
2020 General $2,499 31
2019 General $8,318 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ankur Sethi
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Ankur Sethi were reported at $6,461. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Ankur Sethi Interventional Cardiology median Middle half National median
2019 $8,318 $1,097 $329–$3,048 $163
2020 $2,499 $473 $161–$1,480 $114
2021 $2,341 $677 $233–$1,827 $132
2022 $2,220 $978 $333–$2,724 $149
2023 $7,474 $1,136 $382–$2,986 $160
2024 $5,097 $1,181 $395–$3,326 $164
2025 $6,461 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $9,899 106 payments
  2. Abbott Laboratories $8,918 97 payments
  3. Boston Scientific Corporation $4,008 74 payments
  4. Abiomed $3,522 71 payments
  5. Medtronic Vascular, Inc. $2,562 24 payments
  6. Penumbra, Inc. $2,348 6 payments
  7. AngioDynamics, Inc. $1,510 12 payments
  8. Shockwave Medical, Inc $370 3 payments
  9. Medtronic, Inc. $284 5 payments
  10. Cardiovascular Systems Inc. $250 5 payments
  11. Other $738 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,226 376 payments
  2. Travel and Lodging $15,902 54 payments
  3. Long term medical supply or device loan $282 1 payment
Products named General payments · program years 2019–2025
  1. Indigo $3,708 8 payments
  2. CoreValve Evolut $2,118 21 payments
  3. Impella $2,026 42 payments
  4. AVVIGO Guidance System $1,958 30 payments
  5. Edwards SAPIEN 3 Transcatheter Heart Valve $1,597 11 payments
  6. ANGIOVAC $1,510 12 payments
  7. TRICLIP $1,424 8 payments
  8. Mitra Clip system $1,363 16 payments
  9. EVOQUE $1,349 8 payments
  10. NAVITOR $1,199 6 payments
  11. Other $12,175 226 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

452

Median for Cardiology: 2,533

Drug cost

$358,921

Median for Cardiology: $485,213

Branded share of claims

27%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 13 $290,116
Eliquis Apixaban Brand 44 $55,206
Entresto Sacubitril/Valsartan Brand 11 $9,834
Metoprolol Succinate Generic 70 $909
Clopidogrel Clopidogrel Bisulfate Brand 54 $851
Atorvastatin Calcium Generic 67 $448
Losartan Potassium Generic 45 $365
Amlodipine Besylate Generic 33 $271
Rosuvastatin Calcium Generic 17 $195
Carvedilol Generic 17 $173

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$233,388

Medicare's payments for the services billed

Medicare patients

415

Average age 78

Services billed

1,224

174 women, 241 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 73%
Diabetes 56%
Arthritis 54%
Atrial fibrillation 53%
Chronic kidney disease 48%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

431 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record